Clinical Trial Update: This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating different doses of Brigimadlin (BI 907828) in patients with advanced solid tumors; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neoplasms

Drugs mentioned

• brigimadlin (brigimadlin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasms | Phase 1 | Status: COMPLETED